Loading…
Diversified healthcare company making medical devices (diabetes care, cardiovascular), diagnostics, nutrition products and generic pharmaceuticals.
Diversified healthcare company making medical devices (diabetes care, cardiovascular), diagnostics, nutrition products and generic pharmaceuticals.
Sells through hospitals, pharmacies and retail shelves: glucose sensors replaced every few weeks, diagnostics instruments with tests, heart and brain devices, and nutrition products. The sensors recur, which makes FreeStyle Libre a repeat-purchase growth line beside the one-off device sales.
Moat: wide (brand, installed base, scale). Leading positions across CGM, diagnostics and infant nutrition with strong brand loyalty and device ecosystems.
Headquarters: Abbott Park, Illinois, USA · Founded: 1888 · Employees: 115,000
Size Abbott Laboratories (ABT) is a United States Health Care company (Medical Specialties) with a market value of $190B, the 62nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $109.93 on 6 Nov 2026.
Performance Over six months the shares gained 30.4%, against +27.7% for the median peer and -1.1% for the United States market (cap-weighted) — 7th highest of 14 in its peer set.
Growth Revenue grew 10.0% over the last twelve months (peer median +8.6%); the operating margin is 14.5% (peer median 20.9%).
Valuation It trades at 18.8× forward earnings against a peer median of 25.8× (4th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.0 points above its cost of capital (7.4% WACC).
Credit Abbott Laboratories has 17 bonds outstanding ($30.3B), rated A+ by the agencies and trading like AA- at a weighted spread of 60 bp.
Short interest Short interest is 1.0% of the free float (15 Oct 2026).
Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $48.2B | $44.3B | $42.0B | $40.1B | $43.7B |
| Revenue growth | — | +6% | +5% | -8% | — |
| Gross profit | $28.8B | $23.4B | $21.3B | $20.0B | $22.3B |
| EBITDA | n/a | $11.4B | $10.1B | $9.68B | $11.6B |
| Net income | $4.72B | $6.50B | $13.4B | $5.70B | $6.91B |
| Free cash flow | n/a | $7.39B | $6.35B | $5.06B | $7.80B |
| Capital expenditure | n/a | $2.17B | $2.21B | $2.20B | $1.78B |
| Total debt | n/a | $14.1B | $15.3B | $15.9B | $17.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | $190B | +30% | +10% | 14% | 18.8× | 5.6% |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
| Dexcom DXCM | $29.6B | +31% | +13% | 24% | 27.0× | 18.5% |
| Danaher DHR | $162B | +35% | +6% | 21% | 25.3× | 20.5% |
| Nestle NESN.SW | $266B | +11% | -2% | 16% | 19.0× | 1.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.6% | +15.9% | 7th lowest of 14 |
| 6-month return | +30.4% | +27.7% | 7th highest of 14 |
| Distance from 52-week high | -15.8% | -5.5% | 6th lowest of 14 |
| Revenue growth (TTM) | +10.0% | +8.6% | 5th highest of 14 |
| Operating margin | 14.5% | 20.9% | 3rd lowest of 14 |
| Forward P/E | 18.8× | 25.8× | 4th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 5.6% | 17.2% | 2nd least demanding of 14 |
| Growth delivered (Del g) | +5.1% | +9.7% | 3rd lowest of 14 |
| Hurdle (Req g minus delivered) | +0.5 pp | +7.3 pp | 4th least demanding of 14 |
| ROIC minus cost of capital | +7.0 pp | +1.0 pp | 4th highest of 14 |
| Bond spread | 60 bp | 64 bp | 2nd tightest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | United States | $190B | +30% | +10% | 14% | 18.8× | 5.6% | +5.1% |
| Danaher DHR | United States | $162B | +35% | +6% | 21% | 25.3× | 20.5% | +2.0% |
| Intuitive Surgical ISRG | United States | $157B | +1% | +20% | 32% | 37.5× | 30.8% | +18.2% |
| Thermo Fisher Scientific TMO | United States | $257B | +50% | +8% | 19% | 25.8× | 20.9% | +6.7% |
| Medtronic MDT | United States | $130B | +35% | +10% | 20% | 16.9× | 8.6% | +3.8% |
| Stryker SYK | United States | $124B | +14% | +8% | 25% | 20.4× | 10.6% | +11.8% |
| EssilorLuxottica EL.PA | France | $101B | +12% | +8% | 12% | 26.6× | 19.4% | +14.6% |
| Boston Scientific BSX | United States | $62.0B | -21% | +9% | 21% | 13.8× | 5.0% | +15.2% |
| Edwards Lifesciences EW | United States | $58.9B | +28% | +15% | 29% | 31.4× | 17.2% | +6.7% |
| Becton Dickinson BDX | United States | $57.7B | +43% | -3% | 15% | 16.0× | 9.6% | +6.3% |
| Siemens Healthineers SHL.DE | Germany | $55.9B | +31% | -1% | 15% | 18.9× | 9.0% | +10.1% |
| Idexx Laboratories IDXX | United States | $53.3B | +21% | +12% | 32% | 41.5× | 28.0% | +9.7% |
| Medline MDLN | United States | $52.1B | 0% | +12% | 6% | 26.1× | 17.1% | +9.9% |
| Agilent Technologies A | United States | $49.3B | +51% | +9% | 24% | 26.6× | 22.6% | +5.4% |
Abbott Laboratories has 17 bonds outstanding with $30.3B face value. The agencies rate it A+; its bonds trade like AA-. Weighted yield 5.49%, a spread of 60 bp over government bonds.